リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis

Tsuji, Hideaki 京都大学 DOI:10.14989/doctor.k22883

2021.01.25

概要

Objective: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor prognosis. Because there is no established treatment, we prospectively evaluated the efficacy and safety of a combined immunosuppressive regimen for anti-MDA5-positive DM with ILD.

Methods: Adult Japanese patients with newly onset anti-MDA5-positive DM with ILD (n = 29) were enrolled in multiple centers from 2014 to 2017. They were treated with a regimen of high-dose glucocorticoids (GC), tacrolimus, and intravenous cyclophosphamide (IVCY). Plasmapheresis was used if patients worsened after the regimen started. The primary endpoint was six-month survival, compared with that of a historical control (n = 15) of patients with anti-MDA5-positive DM with ILD who received step-up treatment (high-dose GC and stepwise addition of immunosuppressant). Secondary endpoints were 12-month survival rate, adverse events, and changes in laboratory data.

Results: The combined immunosuppressive regimen group showed significantly higher 6-month survival than the step-up treatment group (89% and 33%, respectively, P < 0.0001). Over 52 weeks, anti-MDA5 titer, serum ferritin level, percent vital capacity, and chest high-resolution computed tomography scores improved. The combined immunosuppressive regimen group received IVCY nearly 20 days earlier with shorter intervals and tended to receive plasmapheresis more often than patients undergoing step-up treatment (n = 15). Cytomegalovirus reactivation was frequently observed over 52 weeks.

Conclusion: A combined immunosuppressive regimen is effective for anti-MDA5-positive DM with ILD. Plasmapheresis can be used for additional effect in intractable disease. Opportunistic infections should be carefully monitored during treatment.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016 Jul;25(8):925-33. PubMed PMID: 27252271. Epub 2016/06/03. eng.

2. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009 Jul;60(7):2193-200. PubMed PMID: 19565506. Epub 2009/07/01. eng.

3. Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010 Mar;49(3):433-40. PubMed PMID: 20015976. Epub 2009/12/18. eng.

4. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care Res (Hoboken). 2016 May;68(5):689-94. PubMed PMID: 26414240. Pubmed Central PMCID: PMC4864500. Epub 2015/09/29. eng.

5. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011 Jul;65(1):25-34. PubMed PMID: 21531040. Pubmed Central PMCID: PMC3167687. Epub 2011/05/03. eng.

6. Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012 Dec;32(12):3909-15. PubMed PMID: 22198664. Epub 2011/12/27. eng.

7. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012 Jul;51(7):1278-84. PubMed PMID: 22378718. Epub 2012/03/02. eng.

8. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013 May;23(3):496-502. PubMed PMID: 22644102. Epub 2012/05/31. eng.

9. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013 Aug;65(8):1316-24. PubMed PMID: 23908005. Epub 2013/08/03. eng.

10. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797. PubMed PMID: 24741583. Pubmed Central PMCID: PMC3987881. Epub 2014/04/18. eng.

11. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13(6):R214. PubMed PMID: 22192091. Pubmed Central PMCID: PMC3334667. Epub 2011/12/24. eng.

12. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986 Nov;29(11):1365-70. PubMed PMID: 3022759. Epub 1986/11/01. eng.

13. Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: Association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012 Nov;64(11):3736-40. PubMed PMID: 22886382. Epub 2012/08/14. eng.

14. Chen Z, Wang Y, Kuwana M, Xu X, Hu W, Feng X, et al. HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis. J Rheumatol. 2017 Sep;44(9):1389-93. PubMed PMID: 28711882. Epub 2017/07/18. eng.

15. Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017 Feb;176(2):395-402. PubMed PMID: 27452897. Epub 2016/07/28. eng.

16. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011 Apr;147(4):391-8. PubMed PMID: 21482889. Epub 2011/04/13. eng.

17. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009 Nov;136(5):1341-7. PubMed PMID: 19581351. Epub 2009/07/08. eng.

18. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012 Sep;51(9):1563-70. PubMed PMID: 22589330. Epub 2012/05/17. eng.

19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344-7. PubMed PMID: 1090839. Epub 1975/02/13. eng.

20. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006 Apr;54(4):597-613. PubMed PMID: 16546580. Epub 2006/03/21. eng.

21. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993 Jan;100(1):124S-7S. PubMed PMID: 8423381. Epub 1993/01/01. eng.

22. Matz EL, Hsieh MH. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology. 2017 Feb;100:16-9. PubMed PMID: 27566144. Epub 2016/08/28. eng.

23. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014 Oct 1(10):CD005590. PubMed PMID: 25269391. Epub 2014/10/02. eng.

24. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004 Aug;8(4):R204-12. PubMed PMID: 15312219. Pubmed Central PMCID: PMC522841. Epub 2004/08/18. eng.

25. Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, et al. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PloS one. 2016;11(4):e0154285. PubMed PMID: 27115353. Pubmed Central PMCID: PMC4846082. Epub 2016/04/27. eng.

26. Sumikawa H, Johkoh T, Colby TV, Ichikado K, Suga M, Taniguchi H, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. American journal of respiratory and critical care medicine. 2008 Feb 15;177(4):433-9. PubMed PMID: 17975197. Epub 2007/11/03. eng.

27. Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, et al. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respiratory investigation. 2018 Nov;56(6):464-72. PubMed PMID: 30150008. Epub 2018/08/29. eng.

28. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2018 Sep 1;198(5):e44-e68. PubMed PMID: 30168753. Epub 2018/09/01. eng.

29. Go DJ, Park JK, Kang EH, Kwon HM, Lee YJ, Song YW, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int. 2016 Jan;36(1):125-31. PubMed PMID: 26223808. Epub 2015/08/01. eng.

30. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005 Sep;32(9):1719-26. PubMed PMID: 16142867. Epub 2005/09/06. eng.

31. Kaieda S, Yoshida N, Yamashita F, Okamoto M, Ida H, Hoshino T, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Mod Rheumatol. 2015;25(6):962-6. PubMed PMID: 24252010. Epub 2013/11/21. eng.

32. Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, et al. Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol. 2015 Jan;25(1):85-9. PubMed PMID: 24716595. Epub 2014/04/11. eng.

33. Nara M, Komatsuda A, Omokawa A, Togashi M, Okuyama S, Sawada K, et al. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. Mod Rheumatol. 2014 Jul;24(4):633-6. PubMed PMID: 24252021. Epub 2013/11/21. eng.

34. Gono T, Kawaguchi Y, Sugiura T, Ichida H, Takagi K, Katsumata Y, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010 Oct;49(10):1878-81. PubMed PMID: 20601655. Epub 2010/07/06. eng.

35. Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, et al. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis. Respir Med. 2015 Sep;109(9):1174-80. PubMed PMID: 26187000. Epub 2015/07/19. eng.

36. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992 May 21;326(21):1380-4. PubMed PMID: 1472183. Epub 1992/05/21. eng.

37. Silveira MG, Selva-O'Callaghan A, Ramos-Terrades N, Arredondo-Agudelo KV, Labrador-Horrillo M, Bravo-Masgoret C. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM : monthly journal of the Association of Physicians. 2016 Jan;109(1):49-50. PubMed PMID: 25784769. Epub 2015/03/19. eng.

38. Fujita Y, Fukui S, Suzuki T, Ishida M, Endo Y, Tsuji S, et al. Anti-MDA5 Antibody-positive Dermatomyositis Complicated by Autoimmune-associated Hemophagocytic Syndrome That Was Successfully Treated with Immunosuppressive Therapy and Plasmapheresis. Internal medicine (Tokyo, Japan). 2018 Dec 1;57(23):3473-8. PubMed PMID: 29984753. Pubmed Central PMCID: PMC6306524. Epub 2018/07/10. eng.

39. Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report. Medicine. 2018 Apr;97(15):e0436. PubMed PMID: 29642214. Pubmed Central PMCID: PMC5908626. Epub 2018/04/12. eng.

40. Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest. 2013 Dec;144(6):1934-6. PubMed PMID: 24297126. Epub 2013/12/04. eng.

41. Sasaki O, Dohi M, Harada H, Imamura M, Tsuchida Y, Yamaguchi K, et al. A Case of Polymyxin b-Immobilized Fiber Column Treatment for Rapidly Progressive Interstitial Pneumonia Associated with Clinically Amyopathic Dermatomyositis. Case Rep Med. 2013;2013:750275. PubMed PMID: 23983712. Pubmed Central PMCID: PMC3741924. Epub 2013/08/29. eng.

42. Okabayashi H, Ichiyasu H, Hirooka S, Akaike K, Kojima K, Jodai T, et al. Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias. BMC pulmonary medicine. 2017 Oct 24;17(1):134. PubMed PMID: 29065861. Pubmed Central PMCID: PMC5655872. Epub 2017/10/27. eng.

43. Yasuda H, Ikeda T, Hamaguchi Y, Furukawa F. Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: The relation between the disease activity and the serum interleukin-6 level. J Dermatol. 2017 May 23. PubMed PMID: 28543432. Epub 2017/05/26. eng.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る